Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022

Published on December 01, 2022

Back to all press releases

New York, NY –December 1, 2022 - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, will host a live webcast to review the Company’s clinical data on the AMELI-01 study (evaluating UCART123) presented at the ASH Annual Meeting, and provide a Company update, on December 13, 2022.

The event will feature presentations by the management team and will be followed by a Q&A.

Cellectis Live Webcast

Tuesday, December 13, 2022

7:30am ET/1:30pm CET

To register and access the live webcast: https://lifescievents.com/event/cellectis-webcast/

Following the live webcast, a replay will be available under the “Events and Webcasts” section on the Investor page of the Company’s website: https://cellectis.com/en/investors/events-and-webcasts/

Download the PDF file